The study also revealed that the ORR of EGFR ex20ins NSCLC patients treated with 300 mg QD of DZD9008 was 41.9%, whereas those treated with 200 mg QD of DZD9008 had an ORR of 45.9%. Here, EGFR is linked to non-small cell lung carcinoma.